EPISODE · Mar 13, 2024 · 39 MIN
All About ViiV: An Interview with CEO Deborah Waterhouse at CROI 2024
from A Shot in the Arm Podcast · host Ben Plumley
ViiV Healthcare is the world’s only pharmaceutical company dedicated exclusively to HIV, and in this episode, Ben meets its CEO, Deborah Waterhouse, to explore the company’s approach to HIV R&D and commercial success - as well as the controversies its global access strategy has attracted for its new long acting injectables. Deborah and Ben find they have much in common beyond both being Brits growing up in the 70s and 80s, from being students of the humanities choosing to make careers in health, to their favorite pop music. https://viivhealthcare.com https://www.unaids.org/en https://www.who.int/health-topics/hiv-aids https://www.cdc.gov/hiv/default.html https://au.int/en/sa/oid #ViiV #pharma #HIV #AIDS #treatment #Prevention #PrEP #dualtherapy #longacting #injectables #globalaccess #globalequity #discrimination #positiveaction #womenleaders #IWD
What this episode covers
ViiV Healthcare is the world’s only pharmaceutical company dedicated exclusively to HIV, and in this episode, Ben meets its CEO, Deborah Waterhouse, to explore the company’s approach to HIV R&D and commercial success - as well as the controversies its global access strategy has attracted for its new long acting injectables. Deborah and Ben find they have much in common beyond both being Brits growing up in the 70s and 80s, from being students of the humanities choosing to make careers in health, to their favorite pop music. https://viivhealthcare.com https://www.unaids.org/en https://www.who.int/health-topics/hiv-aids https://www.cdc.gov/hiv/default.html https://au.int/en/sa/oid #ViiV #pharma #HIV #AIDS #treatment #Prevention #PrEP #dualtherapy #longacting #injectables #globalaccess #globalequity #discrimination #positiveaction #womenleaders #IWD
NOW PLAYING
All About ViiV: An Interview with CEO Deborah Waterhouse at CROI 2024
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m